Case Report

Pilomyxoid astrocytoma of the cerebellar vermis in an elderly patient

Branko Skovrlj, Margaret Pain, Joshua B. Bederson, Mary Fowkes

Departments of Neurosurgery, and Pathology, Mount Sinai School of Medicine, New York, NY, USA

E-mail: *Branko Skovrlj - skovrlj.branko@gmail.com; Margaret Pain - margaret.pain@mountsinai.org; Joshua B Bederson - joshua.bederson@mountsinai.org; Mary Fowkes - mary.fowkes@mountsinai.org

*Corresponding author

Received: 12 October 13 Accepted: 25 November 13 Published: 27 February 14

This article may be cited as:
Skovrlj B, Pain M, Bederson JB, Fowkes M. Pilomyxoid astrocytoma of the cerebellar vermis in an elderly patient. Surg Neurol Int 2014;5:29.
Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2014/5/1/29/127968

Abstract

Background: Pilomyxoid astrocytoma (PMA) has recently been accepted as an aggressive variant of pilocytic astrocytoma with distinct histopathological features. PMAs have been frequently described in the pediatric population with a predilection for the hypothalamic/chiasmatic region.

Case Description: A 72-year-old African American male presented with 6 months of memory loss, difficulty expressing himself, and a progressively worsening gait. Magnetic resonance imaging of the brain demonstrated a heterogeneously enhancing cystic mass centered within the cerebellar vermis with mass effect on the fourth ventricle and ventriculomegaly. The patient underwent placement of a ventriculoperitoneal shunt followed by a surgical resection of the lesion, which after immunohistopathologic evaluation, was diagnosed as a World Health Organization grade II PMA. The patient refused further treatment of the lesion and expired 11 months after initial symptom presentation and 4 months after surgery.

Conclusion: To our knowledge, this is the first report of PMA of the cerebellar vermis in a previously unreported age group. This case report describes the natural history of this type of tumor in a patient who refused adjuvant therapy following surgical resection.

Key Words: Cerebellar vermis, elderly patient, natural history, pilomyxoid astrocytoma

INTRODUCTION

Pilomyxoid astrocytoma (PMA) represents a new clinical entity within neuro-oncology. First described in 1999, Tihan et al. identified a subset of 18 pilocytic astrocytomas with a distinctive pilomyxoid histological pattern as well as a higher recurrence rate than similar tumors with more classical pilocytic astrocytoma characteristics. The majority of tumors in this new category occurred in infants and children and involved the hypothalamic/chiasmatic region. In contrast to the biphasic pattern, Rosenthal fibers and eosinophilic granules characteristic of pilocytic astrocytoma (PA), PMAs typically lack Rosenthal fibers and eosinophilic granules. PMAs are defined by their myxoid matrix with small, compact, piloid, and highly monomorphic cells arranged radially around blood vessels in a pattern that resembles the perivascular rosettes seen in...
Because of these differences, PMAs are thought of as an aggressive variant of the classic pilocytic astrocytoma. As such, PMAs are classified as World Health Organization (WHO) grade II while pilocytic astrocytomas are assigned to the WHO grade I group.

To our knowledge, this is the first report of PMA of the cerebellar vermis in an elderly patient. Moreover, this case report describes the natural history of this type of tumor in a patient who refused additional medical treatment following surgical resection.

**CASE REPORT**

A 72-year-old male with a distant history of alcohol abuse presented with approximately 6 months of memory loss, difficulty expressing himself, and a progressively worsening gait. A magnetic resonance imaging (MRI) of the brain revealed a 2.5 × 3.7 × 2.5 cm heterogeneously enhancing cystic mass centered within the cerebellar vermis with mass effect on the fourth ventricle and mild ventriculomegaly [Figure 1a and b] as well as an 8 × 6 × 4 mm satellite lesion within the right superior cerebellar peduncle [Figure 1c and d]. On examination at an outpatient clinic, the patient had a slight expressive aphasia but was otherwise neurologically intact. At that time, the differential diagnosis of the lesion included primary glioma versus metastatic or granulomatous disease and the decision was made for surgical resection of the lesion.

Routine preoperative testing found the patient to be in rapid atrial fibrillation and he was sent to the emergency room. While undergoing evaluation of the arrhythmia, his rhythm converted to a junctional bradycardia, necessitating placement of transvenous pacemaker. In the absence of other identifiable etiologies for his sudden bradycardia, his cardiac symptoms were attributed to intracranial hypertension secondary to the obstructive hydrocephalus caused by the vermian lesion. A computed tomography (CT) scan of the head revealed ventriculomegaly but no frank hydrocephalus and the patient was taken to the operating room for placement of a ventriculoperitoneal (VP) shunt. Intraoperatively, he was found to have elevated intracranial pressure. His postoperative course was notable for immediate resolution of the cardiac arrhythmia.

Two days following placement of the VP shunt, the patient underwent a suboccipital craniectomy for resection of the cerebellar lesion. Intraoperatively, the lesion was found to be soft and mildly vascular with clean margins relative to the surrounding brain. Pathology specimens were sent for frozen histological analysis and were thought to be most consistent with a diagnosis of glioma. A postoperative MRI revealed a subtotal resection of the lesion. Permanent section of the lesion demonstrated a glial neoplasm composed of astrocytes with elongated, bipolar cytoplasmic processes, forming fascicles and focally, loose perivascular patterns, dispersed within an abundant myxoid background [Figure 2a and b]. The tumor cells had round to irregular, hyperchromatic nuclei, with prominent perinuclear halos infiltrating the molecular layer of the adjacent cerebellar folia. They were strongly immunoreactive for GFAP and WT-1 with a MIB-1 labeling index of greater than 5% [Figure 2c and d]. The lesion was diagnosed as a WHO grade 2 PMA. Postoperatively, the patient did well.
and was discharged to the inpatient rehabilitation service on postoperative day 4 and discharged home 12 days later with residual dizziness and gait imbalance. Following discharge, the patient refused further medical or surgical treatment. His neurologic status and overall health gradually deteriorated and he expired 11 months after initial symptom presentation and 4 months after surgery.

**DISCUSSION**

PMAs have been recently described and accepted as a more aggressive variant of classical PA. Although both the PAs and PMAs present throughout childhood and can occur anywhere in the neuraxis, PMAs have a predilection for the hypothalamic region and tend to afflict very young children.[1,3,7] The mean age at diagnosis for patients with PMA is 18 months, compared with 58 months for patients diagnosed with PA.[7] There are very few reports of PMA in adults described in the literature,[2,4,6,10,12,14,16] and only one with a lesion in the posterior fossa.[9] To date, there have been no reports of PMA arising from the cerebellar parenchyma in an elderly person.

Clinically, PMAs have been shown to behave more aggressively than PAs. Komotar et al.[7] compared the long-term outcomes for 21 patients with hypothalamic PMAs with the outcomes in 42 patients with PAs in the same location with a mean follow-up of 26 months. They found that patients with PMA had a higher rate of local recurrence than those with PA (76% and 50%, respectively). They also noted that the PMA group had a 14% tumor dissemination rate into the cerebrospinal fluid while this was not reported in a single patient in the PA group. More importantly, patients with PMA demonstrated significantly shorter progression-free (mean duration 26 and 147 months for those with PMA and PA, respectively; \( P < 0.001 \)) and overall (mean duration 63 and 213 months, respectively; \( P < 0.001 \)) survival times than those with PA. When matched for age, patients with PMA continued to exhibit significantly shorter progression-free and overall survival times than those with PA. The study also demonstrated that 33% of patients with PMA died of their disease, compared with 17% of those with PA.

There is currently no consensus on the standard of care for the management of PMAs. At present, PMAs are managed in a similar manner to PAs. Gross total resection (GTR), when possible, is the primary treatment strategy. GTR has been demonstrated to be the most reliable predictor of outcome in children with low-grade gliomas when surgery can be performed without excessive morbidity.[17] Adjuvant therapy, either chemotherapy or radiotherapy, is instituted if tumor recurs following GTR, neurologic deficits remain following subtotal resection and in cases of subtotal resection with evidence of tumor growth on postoperative imaging, even in the absence of symptoms.[13] With less than a dozen reported cases of PMA in adults, there is no level 1 evidence to guide management of PMA in this population. Instead, recommendations are based on experience and expert opinion derived from individual cases published in the literature. In one center, unless GTR is achieved, adjuvant chemotherapy is started immediately after surgery, without waiting for tumor growth or recurrence and concomitant radiotherapy is recommended in adult patients.[11] In cases of refractory or disseminated PMA, some authors recommend the use of tyrosine kinase inhibitors as an alternative treatment.[9] As more cases of PMA emerge and clinicians gain more experience with PMA in the future, more definitive guidelines are certain to emerge.

**CONCLUSION**

To our knowledge this is the first report of PMA presenting in the cerebellum of an elderly patient. Our patient underwent subtotal surgical resection of the lesion and refused postoperative adjuvant therapy. He died from complications secondary to disease progression 11 months after initial diagnosis and 4 months following surgery. This report outlines the occurrence of PMA in the adult population and emphasizes the need for aggressive postoperative adjuvant therapy in adults with subtotal tumor resection. The current treatment recommendations based on a small sample of case reports suggest that aggressive surgical resection followed by adjuvant therapy with either chemotherapy and/or radiation therapy should be tailored to individual patients based on their age and disease characteristics.

**REFERENCES**

1. Clark GB, Henry JM, McKeever PE. Cerebral pilocytic astrocytoma. Cancer 1985;56:1128-33.
2. Enting RH, van der Graaf WT, Kros JM, Heesters M, Metzemaekers J, den Dunnen W. Radiotherapy plus concomitant and adjuvant temozolomide for leptomeningeal pilomyxoid astrocytoma: A case study. J Neurooncol 2006;80:107-8.
3. Farwell JR, Dohrmann Gj, Flannery JT. Central nervous system tumors in children. Cancer 1977;40:123-32.
4. Fuller CE, Frankel B, Smith M, Rodziwitz G, Landas SK, Caruso R, et al. Suprasellar monomorphous pilomyxoid neoplasm: An ultrastructural analysis. Clin Neuropathol 2001;20:256-62.
5. Gottfried ON, Fuhts DW, Townsend JJ, Couldwell WT. Spontaneous hemorrhage associated with a pilomyxoid astrocytoma. Case report. J Neurosurg 2003;99:416-20.
6. Juso-S-Torres I, Alcázar-Vaquero L, Gómez-Angulo JC, Navarro-Torres R, López-Serrano R, García-Miralles N. Leptomeningeal spread of an intramedullary cervical pilocytic astrocytoma: A case report and literature review. Neurocirugía (Astur) 2011;22:445-51.
7. Komotar RJ, Burger PC, Carson BS, Brem H, Olivi A, Goldthwaite PT, et al. Pilocytic and pilomyxoid hypothalamic/chiasmatic astrocytomas. Neurosurgery 2004;54:72-9.
8. Komotar RJ, Mocco J, Carson BS, Sughrue ME, Zacharia BE, Sisti AC, et al. Pilomyxoid astrocytoma: A review. MedGenMed 2004;6:62.
9. Komotar RJ, Mocco J, Jones JE, Zacharia BE, Tihan T, Feldstein NA, et al.
Pilomyxoid astrocytoma: Diagnosis, prognosis, and management. Neurosurg Focus 2005;18:E7.

10. Komotar RJ, Mocco J, Zacharia BE, Wilson DA, Kim PY, Canoll PD, et al. Astrocytoma with pilomyxoid features presenting in an adult. Neuropathology 2006;26:89-93.

11. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. Pilomyxoid astrocytoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. The 2007 WHO classification of tumor of the central nervous system, 4th ed. Lyon: IARC Press; 2007. p. 20-1.

12. Mendiratta-Lala M, Kader Ellika S, Gutierrez JA, Patel SC, Jain R. Spinal cord pilomyxoid astrocytoma: An unusual tumour. J Neuroimaging 2007;17:371-4.

13. Omura T, Nawashiro H, Osada H, Shima K, Tsuda H, Shinsuke A. Pilomyxoid astrocytoma of the fourth ventricle in an adult. Acta Neurochir (Wien) 2008;150:1201-6.

14. Sajadi A, Janzer RC, Lu TL, Duff JM. Pilomyxoid astrocytoma of the spinal cord in an adult. Acta Neurochir (Wien) 2008;150:729-31.

15. Tihan T, Fisher PG, Kepner JL, Godfraind C, McComb RD, Goldthwaite PT, et al. Pediatric astrocytomas with monomorphous pilomyxoid features and a less favorable outcome. J Neuropathol Exp Neurol 1999;58:1061-8.

16. Toyoda K, Tsutsumi K, Ono T, Takahata H, Toda K, Ito M, et al. Pilomyxoid astrocytoma presenting in an elderly patient: A case report. No Shinkei Geka 2009;37:1123-8.

17. Wallner KE, Gonzales MF, Edwards MS, Wara WM, Sheline GE. Treatment results of juvenile pilocytic astrocytoma. J Neurosurg 1988;69:171-6.